Following the announcement of Valeant Pharmaceuticals International Inc.’s plans to acquire Raleigh, North Carolina-based Salix Pharmaceuticals Ltd. for $10.1 billion late last month, a rival $11.2 billion bid for the target emerged Wednesday from Endo International plc.
Skadden, Arps, Slate, Meagher & Flom, a firm familiar with twisted pharmaceutical takeover battles, is serving as lead counsel to Endo on its offer for Salix. The firm is also handling finance and antitrust aspects of Valeant’s bid for the company. Skadden declined to comment on its work representing both potential Salix acquirers.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
